Dose-Effect Determination of a Neuroprotector Fraction Standardized in Coumarins of <i>Tagetes lucida</i> and Bioavailability

• Main Authors: Anislada Santibáñez (Author), Maribel Herrera-Ruiz (Author), Manasés González-Cortazar (Author), Pilar Nicasio-Torres (Author), Ashutosh Sharma (Author), Enrique Jiménez-Ferrer (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Neurodegeneration has been associated with chronic inflammation states in the brain. For this reason, attention has been directed to drugs indicated as anti-inflammatory as possible therapies for the treatment of said conditions. <i>Tagetes lucida</i> has been widely used as a folk remedy in illnesses associated with the central nervous system and inflammatory ailments. Among the compounds that stand out in the plant against these conditions are coumarins, such as 7-<i>O</i>-prenyl scopoletin, scoparone, dimethylfraxetin, herniarin, and 7-<i>O</i>-prenylumbelliferone. Therefore, the relationship between the therapeutic effect and the concentration was evaluated through pharmacokinetic and pharmacodynamic studies, including vascular permeability evaluation by blue Evans and pro- and anti-inflammatory cytokines quantification, under a neuroinflammation model induced by lipopolysaccharide by the oral administration of three different doses (5, 10, and 20 mg/kg) of a bioactive fraction of <i>T. lucida</i>. In the present study, it was found that all doses showed a neuroprotective and immunomodulatory effect, although the doses of 10 and 20 mg/kg were able to exert their effect for a longer time and to a greater extent. The protective effects of the fraction may be mainly associated with the DR, HR, and SC coumarins due to their structural profile and plasmatic and brain tissue bioavailability.

Item Description

10.3390/pharmaceutics15030967
1999-4923